Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 6Completed 6Active not recruiting 4Unknown 3Terminated 2Withdrawn 1Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 5Pancreatic Neoplasms 2Ovarian Neoplasms 2Sarcoma 1Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Follicular 1Fallopian Tube Neoplasms 1Estrogen Receptor Positive 1Colorectal Neoplasms 1Carcinoma, Endometrioid 1COVID-19 1Brain Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Cisplatin 9pembrolizumab 7Radiosurgery 6Gemcitabine 6Paclitaxel 5Dexamethasone 5Taxes 4Carboplatin 4trametinib 3ibrutinib 3Surveys and Questionnaires 3Standard of Care 3Radiotherapy 3Nivolumab 3Magnetic Resonance Spectroscopy 3Lenalidomide 3Fluorouracil 3Erlotinib Hydrochloride 3Blood Specimen Collection 3Ascorbic Acid 3venetoclax 2veliparib 2tocilizumab 2pazopanib 2obinutuzumab 2naquotinib 2lenvatinib 2fludarabine 2enzalutamide 2Vemurafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Neoplasms × palbociclib × Clear all
NCT03123744 2018-06-21

Histology-Independent Study of Palbociclib in Patients With Advanced Cancer

University of California, San Diego

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡